Novo Nordisk A/S Securities Lawsuit for Potential Shareholder Recovery

Strategic Insights -

A class action lawsuit was filed against Novo Nordisk A/S (NYSE: NVO) seeking to recover losses of shareholders who were allegedly harmed by securities fraud between May 7, 2025, and July 28, 2025. The lawsuit claims that the company made misleading statements about its growth potential, understating the impact of the personalization exception to the compounded GLP-1 exclusion and overstating the likelihood of patients switching to Novo's branded alternatives. On July 29, 2025, Novo announced a lower sales and profit outlook, which led to a significant decline in the company's stock price.

Key Takeaways:

  • A class action lawsuit was filed against Novo Nordisk A/S on behalf of shareholders who suffered losses due to alleged securities fraud between May 7, 2025, and July 28, 2025.
  • The lawsuit claims that the company made misleading statements about its growth potential, including underestimating the impact of the personalization exception to the compounded GLP-1 exclusion and overstating the likelihood of patients switching to Novo's branded alternatives.
  • On July 29, 2025, Novo announced a lower sales and profit outlook, citing "lowered growth expectations for the second half of 2025" and "the persistent use of compounded GLP-1s, slower-than-expected market expansion, and competition".
  • The stock price of Novo declined dramatically following the announcement, falling from $69.00 per share on July 28, 2025, to $53.94 per share on July 29, 2025, a decline of about 21.83% in a single day.
  • Shareholders who suffered losses in Novo stock during the relevant time frame may be eligible to seek a recovery.
  • Levi & Korsinsky LLC, a nationally-recognized securities litigation firm, has expertise in representing investors in complex securities litigation and a track record of winning high-stakes cases.

Statistics:

  • Date of lawsuit filing: Not specified (between May 7, 2025, and July 28, 2025)
  • Decline in stock price: 21.83% in a single day (from $69.00 to $53.94)
  • Time period of alleged securities fraud: May 7, 2025 - July 28, 2025

Sources:

  • Newsfile Corp.
  • Levi & Korsinsky LLP
  • Novo Nordisk A/S (NYSE: NVO)
  • Securities and Exchange Commission (SEC) regulations